By: Alvaro Fernandez
We were very glad this morning to find this customer review in Amazon.com, discussing our new book:
“My family has a history of dementia and Alzheimer’s, so my wife and I are always on the lookout for new and helpful information about keeping our brains strong as we age. We’ve read more than a few and I haven’t written reviews of any of them. I wanted to share a bit about why I did like this book and what prompted me to take the time to write a review. I found this book to be bursting with useful information. Read the rest of this entry »
Time for SharpBrains’ May 2013 e-newsletter, which features a variety of articles offering a more optimistic and evidence-based approach to brain and mental health than current practices.
First of all, let us highlight that Scientific American just published an excellent review of our new book. The author sums it up by saying that “…I wish I had read this awesome guide when I was much younger…I find the emerging field of neuroplasticity immensely exciting, and guides like this one are both hopeful and reasonable.” As a reader points out, the word “awesome” does not appear often in science-oriented publications…so we are especially proud to see the book merit such treatment.
That’s it for now. Have a stimulating June!
Transforming Diagnosis (article by Thomas Insel, Director of the NIMH): “In a few weeks, the American Psychiatric Association will release its new edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)…While DSM has been described as a “Bible” for the field, it is, at best, a dictionary, creating Read the rest of this entry »
Dementia Care Cost Is Projected to Double by 2040 (The New York Times):
“The most rigorous study to date of how much it costs to care for Americans with dementia found that the financial burden is at least as high as that of heart disease or cancer, and is probably higher. And both the costs and the number of people with dementia will more than double within 30 years, skyrocketing at a rate that rarely occurs with a chronic disease…The RAND results show that nearly 15 percent of people aged 71 or older, about 3.8 million people, have dementia. By 2040, the authors said, that number will balloon Read the rest of this entry »
Drugs for Early-Stage Alzheimer’s (good New York Times editorial):
“The Food and Drug Administration has proposed lowering the bar for approving drugs to treat people at the earliest stages of Alzheimer’s disease, before they have developed any serious impairment or overt dementia. The goal is commendable — to find ways to prevent or slow the progression of this terrible disease before it can rob people of their mental capacities. But the proposal raises troubling questions as to whether the agency would end up approving drugs that provide little or no clinical benefit yet Read the rest of this entry »
By: Dr. Pascale Michelon
According to a new study, the population with Alzheimer’s Disease in the US will triple by 2050: from 4.7 millions in 2010 to 13.8 millions. This emphasizes the urgent need for more research to find preventive measures, and for more enlightened public health initiatives and individual lifestyles designed to decrease dementia risks and delay onset of symptoms.
Between 1993 and 2011, researchers followed more than 10,000 individuals 65 and older. Participants were interviewed and assessed for dementia every three years. Read the rest of this entry »
By: David Coleiro
Much of healthcare delivery has traditionally been set-up to deal with a ‘brainless body’; yet we consistently complain that we cannot change patient and consumer behaviours and maintain adherence to treatment programmes. Healthcare systems are now recognising the limits of this model and that there are major benefits to better comprehending and engaging cognitive function Read the rest of this entry »